Key result
Oral pravastatin lowers total cholesterol by ~31% in hyperlipidemic rats.
A new animal model of hyperlipidemia is being developed using the nonionic surfactant poloxamer 407 (P-407). We investigated the impact of pravastatin on P-407-induced hyperlipidemia. Twenty rats received P-407 300 mg intraperitoneally to induce hyperlipidemia, and 20 control rats received saline injection. Pravastatin was administered orally to an equal number of rats in both groups using three different regimens. A fourth group did not receive pravastatin. At 24 hours after injection, total cholesterol levels in two of the pravastatin groups were 28% and 34% lower than those in animals that did not receive pravastatin (p < or = 0.01). At 48 hours, triglyceride levels were significantly lower in all pravastatin groups (21-44%) versus animals not receiving pravastatin. Pravastatin diminished the effects of P-407 on lipoproteins. This new animal model may be useful in screening for investigational antihyperlipidemic agents.
No takes yet. Share an insight, caveat, or question.
Porter et al. (1995) studied Poloxamer 407-induced hyperlipidemia (n=40). Pravastatin vs. No pravastatin was evaluated on Total cholesterol levels at 24 hours and triglyceride levels at 48 hours (p=<= 0.01). Oral pravastatin lowered total cholesterol by 28-34% (p<=0.01) at 24 hours and triglycerides by 21-44% at 48 hours in P-407-induced hyperlipidemic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: